Proposed Rules of Evidence Amendment
Client Alert | 1 min read | 07.25.06
The Advisory Committee on the Federal Rules of Evidence has proposed a change that would promote cooperation with federal regulatory, investigative and enforcement authorities and at the same time remove the fear that such cooperation would permit discovery by third parties of attorney-client privileged and work product protected materials that are shared with these federal authorities. The proposed rule declares that these disclosures do not operate as a waiver of the privilege or protection in favor of non-governmental persons or entities.
The proposed rule, Rule 502, also states the disclosure of privileged and protected communications and information does not operate as a waiver in a state or federal proceeding if the disclosure is inadvertent and made in connection with federal litigation or administrative proceedings and if the holder of the privilege or work product protection took reasonable precautions to prevent disclosure and reasonably prompt measures to rectify the error.
Additionally, the proposed rule would limit the scope of a waiver by disclosure of attorney-client privileged or work product protected communications or information. No longer would subject matter waiver be required. Instead, only undisclosed communications or information that ought in fairness to be considered with the disclosed communication or information would be subject to waiver.
The proposed rule requires Congressional enactment. It deserves support for it resolves circuit splits with respect to selective waiver and inadvertent disclosure. However, whether the proposed rule will achieve another of its goals – reducing the costs involved in reviewing and protecting material that is privileged or work product – reducing the costs involved in reviewing and protecting material that is privileged or work product – remains to be seen. Plainly, though, the proposal is a step in the right direction.
Contacts
Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 06.26.26
Client Alert | 4 min read | 06.25.26
Twin Executive Orders Seek to Spur Quantum Leap in Technology and Cybersecurity
Client Alert | 7 min read | 06.24.26


